Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.35 |
| ▸ | HSD11B2 | P80365 | 4/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2393815 | 1.00 | PDPK1 (0.96) | PDPK1ALDH1A1MEN1MAPTBLM | |
| SCHEMBL6850314 | 0.98 | — | — | |
| SCHEMBL348289 | 0.91 | — | — | |
| SCHEMBL18501325 | 0.82 | PDPK1 (0.71) | PDPK1DRD4 | |
| SCHEMBL18501324 | 0.82 | PDPK1 (0.71) | PDPK1DRD4 | |
| SCHEMBL16253565 | 0.82 | PDPK1 (0.71) | PDPK1DRD4 | |
| SCHEMBL18501338 | 0.79 | PDPK1 (0.62) | PDPK1ALDH1A1MEN1MAPTBLM | |
| SCHEMBL16253536 | 0.79 | PDPK1 (0.62) | PDPK1 | |
| SCHEMBL16253519 | 0.79 | PDPK1 (0.62) | PDPK1 | |
| SCHEMBL24566373 | 0.78 | PDPK1 (0.66) | PDPK1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113460-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2010-05-06 | — | — | US | disclosed |
| US-20100113460-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2010-05-06 | — | — | US | disclosed |
| WO-2008116339-A2 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113460-A1 | Organic Compounds | CYP2B6, CYP2A6, CYP2A13 | PDPK1 2126/4885ALDH1A1 78/4885MEN1 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.